The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

Atherosclerosis

Volumn 202, Issue 2, 2009, Pages 321-329

  Stephens, Jeffrey W ^a,b   Khanolkar, Manish P ^a   Bain, Stephen C ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Biomarker; Cardiovascular disease; Diabetes; Oxidative stress; Risk

Indexed keywords

ANTIOXIDANT; FREE RADICAL; GLUCOSE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MARKER; REACTIVE OXYGEN METABOLITE;

BIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; HUMAN; ISCHEMIC HEART DISEASE; MEASUREMENT; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PLASMA; PREDICTION; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; OXIDATIVE STRESS; RISK FACTORS;

EID: 58549104535     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.06.006     Document Type: Review

References (99)

1. Orchard T. Diabetes: a time for excitement-and concern. Hopeful signs exist that the ravages of diabetes can be tamed. BMJ 317 (1998) 691-692
2. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl. 5 (1997) S1-85
3. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
4. Garcia M.J., McNamara P.M., Gordon T., and Kannel W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23 (1974) 105-111
5. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30 (1987) 123-131
6. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
7. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. American Diabetes Association. Diabetes Care 1989;12:573-9.
8. Wilson P.W. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 7 (1994) 7S-12S
9. Futterman L.G., and Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care 7 (1998) 240-244
10. Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47 (2001) 403-411
11. Pyorala K., Laakso M., and Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3 (1987) 463-524
12. Stephens J.W., Ambler G., Vallance P., et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. Eur J Cardiovasc Prev Rehabil 11 (2004) 521-528
13. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
14. Maritim A.C., Sanders R.A., and Watkins III J.B. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17 (2003) 24-38
15. Harrison D., Griendling K.K., Landmesser U., Hornig B., and Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 91 (2003) 7A-11A
16. Suzuki Y.J., Forman H.J., and Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 22 (1997) 269-285
17. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23 (2002) 599-622
18. Odetti P., Garibaldi S., Noberasco G., et al. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects. Acta Diabetol 36 (1999) 179-183
19. Davi G., Ciabattoni G., Consoli A., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
20. Ceriello A., Quagliaro L., Catone B., et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25 (2002) 1439-1443
21. Telci A., Cakatay U., Kayali R., et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 32 (2000) 40-43
22. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., and Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44 (1995) 1054-1058
23. Maddux B.A., See W., Lawrence Jr. J.C., et al. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes 50 (2001) 404-410
24. Maechler P., Jornot L., and Wollheim C.B. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J Biol Chem 274 (1999) 27905-27913
25. Ceriello A., and Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24 (2004) 816-823
26. Tretter L., and Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20 (2000) 8972-8979
27. Rudich A., Tirosh A., Potashnik R., et al. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47 (1998) 1562-1569
28. Talior I., Yarkoni M., Bashan N., and Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 285 (2003) E295-E302
29. Paolisso G., and Giugliano D. Oxidative stress and insulin action: is there a relationship?. Diabetologia 39 (1996) 357-363
30. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 52 (2003) 1-8
31. Tiedge M., Lortz S., Drinkgern J., and Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46 (1997) 1733-1742
32. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., and Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52 (2003) 581-587
33. Radomski M.W., Palmer R.M., and Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92 (1987) 639-646
34. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
35. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
36. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28 (2000) 1815-1826
37. Ceconi C., Boraso A., Cargnoni A., and Ferrari R. Oxidative stress in cardiovascular disease: myth or fact?. Arch Biochem Biophys 420 (2003) 217-221
38. Stephens J.W., Gable D.R., Hurel S.J., et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 52 (2006) 446-452
39. Witztum J.L., and Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 11 (2001) 93-102
40. Hessler J.R., Morel D.W., Lewis L.J., and Chisolm G.M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3 (1983) 215-222
41. Heinecke J.W., Rosen H., and Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 74 (1984) 1890-1894
42. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81 (1984) 3883-3887
43. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2243-2247
44. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
45. Weinbrenner T., Cladellas M., Isabel Covas M., et al. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 168 (2003) 99-106
46. Scheffer P.G., Bos G., Volwater H.G., et al. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabet Med 20 (2003) 563-567
47. Campos H., Genest Jr. J.J., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12 (1992) 187-195
48. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
49. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
50. Lamarche B., St-Pierre A.C., Ruel I.L., et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17 (2001) 859-865
51. Anber V., Griffin B.A., McConnell M., Packard C.J., and Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124 (1996) 261-271
52. Bjornheden T., Babyi A., Bondjers G., and Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123 (1996) 43-56
53. Wood L.G., Gibson P.G., and Garg M.L. A review of the methodology for assessing in vivo antioxidant capacity. J Sci Food Agric 86 (2006) 2057-2066
54. Halliwell B.G.J. Free radicals in biology and medicine (1989), Clarendon Press, Oxford
55. Lynch R.E., and Fridovich I. Permeation of the erythrocyte stroma by superoxide radical. J Biol Chem 253 (1978) 4697-4699
56. Mao G.D., and Poznansky M.J. Electron spin resonance study on the permeability of superoxide radicals in lipid bilayers and biological membranes. FEBS Lett 305 (1992) 233-236
57. Wagner E.S., White W., Jennings M., and Bennett K. The entrapment of [14C]ascorbic acid in human erythrocytes. Biochim Biophys Acta 902 (1987) 133-136
58. Okamura M. Uptake of L-ascorbic acid and L-dehydroascorbic acid by human erythrocytes and HeLa cells. J Nutr Sci Vitaminol (Tokyo) 25 (1979) 269-279
59. Iheanacho E.N., Stocker R., and Hunt N.H. Redox metabolism of vitamin C in blood of normal and malaria-infected mice. Biochim Biophys Acta 1182 (1993) 15-21
60. May J.M., Qu Z.C., and Whitesell R.R. Ascorbic acid recycling enhances the antioxidant reserve of human erythrocytes. Biochemistry 34 (1995) 12721-12728
61. Sampson M.J., Gopaul N., Davies I.R., Hughes D.A., and Carrier M.J. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 25 (2002) 537-541
62. Packer J.E., Slater T.F., and Willson R.L. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 278 (1979) 737-738
63. Stocker R., Weidemann M.J., and Hunt N.H. Possible mechanisms responsible for the increased ascorbic acid content of Plasmodium vinckei-infected mouse erythrocytes. Biochim Biophys Acta 881 (1986) 391-397
64. Miller N.J., Rice-Evans C., and Davies M.J. A new method for measuring antioxidant activity. Biochem Soc Trans 21 (1993) 95S
65. Rice-Evans C., and Miller N.J. Total antioxidant status in plasma and body fluids. Methods Enzymol 234 (1994) 279-293
66. McLemore J.L., Beeley P., Thorton K., et al. Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of serum samples from patients infected with HIV: elevated lipid hydroperoxide concentrations and depleted total antioxidant capacity of serum samples. Am J Clin Pathol 109 (1998) 268-273
67. Talmud P.J., Stephens J.W., Hawe E., et al. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet 69 (2005) 613-622
68. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37 (2004) 277-285
69. Prior R.L., and Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med 27 (1999) 1173-1181
70. Morrow J.D., Hill K.E., Burk R.F., et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87 (1990) 9383-9387
71. Lynch S.M., Morrow J.D., Roberts II L.J., and Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 93 (1994) 998-1004
72. Morrow J.D., and Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36 (1997) 1-21
73. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 58 (1998) 319-325
74. Wu T., Willett W.C., Rifai N., et al. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among US. men and women?. J Am Coll Cardiol 48 (2006) 973-979
75. Meisinger C., Baumert J., Khuseyinova N., Loewel H., and Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112 (2005) 651-657
76. Ujihara N., Sakka Y., Takeda M., et al. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 58 (2002) 109-114
77. Thomson M.J., Puntmann V., and Kaski J.C. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment?. Cardiovasc Drugs Ther 21 (2007) 195-210
78. Tomono S., Kawazu S., Kato N., et al. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscler Thromb 1 (1994) 98-102
79. Kawakami A., Tani M., Chiba T., et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 25 (2005) 424-429
80. Cushing S.D., Berliner J.A., Valente A.J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87 (1990) 5134-5138
81. Rajavashisth T.B., Andalibi A., Territo M.C., et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344 (1990) 254-257
82. Kawakami A., Tanaka A., Nakano T., Saniabadi A., and Numano F. Stimulation of arterial smooth muscle cell proliferation by remnant lipoprotein particles isolated by immuno-affinity chromatography with anti-apo A-I and anti-apo B-100. Horm Metab Res 33 (2001) 67-72
83. Kawakami A., Tanaka A., Chiba T., et al. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation 108 (2003) 2679-2688
84. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., and Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109 (2004) 1022-1028
85. Delerive P., Furman C., Teissier E., et al. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 471 (2000) 34-38
86. Stiko-Rahm A., Hultgardh-Nilsson A., Regnstrom J., Hamsten A., and Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 12 (1992) 1099-1109
87. Saniabadi A.R., Umemura K., Shimoyama M., et al. Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins. Thromb Haemost 77 (1997) 996-1001
88. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (1990) 160-162
89. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am J Nephrol 18 (1998) 344-350
90. Murphy J.E., Tedbury P.R., Homer-Vanniasinkam S., Walker J.H., and Ponnambalam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182 (2005) 1-15
91. Ghiselli A., Serafini M., Natella F., and Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med 29 (2000) 1106-1114
92. Morrow J.D., and Roberts II L.J. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 233 (1994) 163-174
93. Yamamoto Y., Frei B., and Ames B.N. Assay of lipid hydroperoxides using high-performance liquid chromatography with isoluminal chemiluminescence detection. Methods Enzymol 186 (1990) 371-380
94. Hughes H., Smith C.V., Tsokos-Kuhn J.O., and Mitchell J.R. Quantitation of lipid peroxidation products by gas chromatography-mass spectrometry. Anal Biochem 152 (1986) 107-112
95. Pincemail J., Defraigne J.O., and Limet R. Oxidative stress in clinical situations--fact or fiction?. Eur J Anaesthesiol 13 (1996) 219-234
96. Halliwell B., and Grootveld M. The measurement of free radical reactions in humans. Some thoughts for future experimentation. FEBS Lett 213 (1987) 9-14
97. Young I.S., and Trimble E.R. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 28 Pt 5 (1991) 504-508
98. Repine J.E., Bast A., and Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 156 (1997) 341-357
99. Svoboda P., and Kasai H. Simultaneous HPLC analysis of 8-hydroxydeoxyguanosine and 7-methylguanine in urine from humans and rodents. Anal Biochem 334 (2004) 239-250